Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2026)
Quantum Biopharma recorded quarterly Income from Continuing Operations of 2989159.0 in Q1 2026, down 18.08% quarter-over-quarter from 2531448.0 in Q4 2025, and up 12.59% year-over-year from 2654971.47 in Q1 2025.
Quantum Biopharma's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 2989159.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 12.59% year-over-year to 2989159.0; the TTM figure through Mar 2026 stood at 15260705.0 (down 15.88% YoY), while the FY2025 annual figure was 15460437.0, up 4.38% from the prior year.
- Income from Continuing Operations came in at 2989159.0 for Q1 2026 at Quantum Biopharma, down from 2531448.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 25292797.0 in Q2 2023 to a low of 9845642.0 in Q1 2023.
- A 5-year average of 1438665.14 and a median of 3376001.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 274.78% in 2023 and surged 76.95% in 2024, its largest moves.
- Quantum Biopharma's Income from Continuing Operations stood at 5633288.0 in 2022, then plunged by 227.63% to 7189574.0 in 2023, then jumped by 70.88% to 2093300.0 in 2024, then dropped by 20.93% to 2531448.0 in 2025, then slipped by 18.08% to 2989159.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2989159.0, 2531448.0, and 4769697.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -453.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.99 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Jun 30, 2025 | -4.97 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -2.09 Mn |
| Sep 30, 2024 | -4.19 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -3.33 Mn |
| Jun 30, 2023 | 25.29 Mn |
| Mar 31, 2023 | -9.85 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Jun 30, 2021 | -12.71 Mn |
| Mar 31, 2021 | 9.78 Mn |
| Sep 30, 2020 | -13.18 Mn |
| Jun 30, 2020 | -3.53 Mn |
| Mar 31, 2020 | -5.04 Mn |
| Dec 31, 2019 | -11.59 Mn |
| Mar 31, 2019 | -1.81 Mn |